Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

asthma drug

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

- PMLiVE

GSK’s Nucala posts mixed results in COPD

Conflicting late-stage trials throw doubt on its prospects

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

- PMLiVE

Walmsley steps up to chief executive role at GSK

The firm's first female CEO, she takes over from Sir Andrew Witty

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE

Riding the wave of digital disruption

The challenges and rewards of meeting consumer expectations

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

- PMLiVE

Biotech leaders slam Trump over immigration order

Former Teva CEO Jeremy Levin heads open letter expressing “deep concern and opposition”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links